{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T03:20:18Z","timestamp":1788405618937,"version":"build-2803163510"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,2,25]],"date-time":"2024-02-25T00:00:00Z","timestamp":1708819200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,2,25]],"date-time":"2024-02-25T00:00:00Z","timestamp":1708819200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Thromb Thrombolysis"],"DOI":"10.1007\/s11239-024-02951-w","type":"journal-article","created":{"date-parts":[[2024,2,25]],"date-time":"2024-02-25T08:02:11Z","timestamp":1708848131000},"page":"587-597","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["A systematic review of therapeutic enoxaparin dosing in obesity"],"prefix":"10.1007","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3183-5214","authenticated-orcid":false,"given":"Maya R.","family":"Chilbert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly","family":"Zammit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1596-2459","authenticated-orcid":false,"given":"Uzma","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3050-9794","authenticated-orcid":false,"given":"Amanda","family":"Devlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4671-8662","authenticated-orcid":false,"given":"Sara","family":"Radparvar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Schuler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2378-1842","authenticated-orcid":false,"given":"Ashley E.","family":"Woodruff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,25]]},"reference":[{"key":"2951_CR1","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1177\/1060028018768449","volume":"52","author":"J Sebaaly","year":"2018","unstructured":"Sebaaly J, Covert K (2018) Enoxaparin dosing at extremes of weight: literature review and dosing recommendations. Ann Pharmacother 52:898\u2013909. https:\/\/doi-org.gate.lib.buffalo.edu\/10.1177\/1060028018768449","journal-title":"Ann Pharmacother"},{"key":"2951_CR2","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1067\/mcp.2002.127114","volume":"72","author":"GJ Sanderink","year":"2002","unstructured":"Sanderink GJ, Le Liboux A, Jariwala N, Harding N, Ozoux ML, Shukla U, Montay G, Boutouyrie B, Miro A (2002) The pharmacokinetics and pharmacodynamics of enoxaparin in obese volunteers. Clin Pharmacol Ther 72:308\u2013318. https:\/\/doi.org\/10.1067\/mcp.2002.127114","journal-title":"Clin Pharmacol Ther"},{"key":"2951_CR3","unstructured":"Package insert : https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/020164s085lbl.pdf"},{"key":"2951_CR4","unstructured":"World Health Organization (2023) Obesity and Overweight. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/obesity-and-overweight. Accessed 17 November 2023"},{"key":"2951_CR5","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1055\/s-0038-1651032","volume":"62","author":"MN Levine","year":"1989","unstructured":"Levine MN, Planes A, Hirsh J, Goodyear M, Vochelle N, Gent M (1989) The relationship between anti-factor xa level and clinical outcome in patients receiving enoxaparine low molecular weight heparin to prevent deep vein thrombosis after hip replacement. Thromb Haemost 62:940\u2013944. https:\/\/doi.org\/10.1055\/s-0038-1651032","journal-title":"Thromb Haemost"},{"key":"2951_CR6","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1161\/01.CIR.0000136830.65073.C7","volume":"110","author":"G Montalescot","year":"2004","unstructured":"Montalescot G, Collet JP, Tanguy ML et al (2004) Anti-xa activity relates to survival and efficacy in unselected acute coronary syndrome patients treated with enoxaparin. Circulation 110:392\u2013398. https:\/\/doi.org\/10.1161\/01.CIR.0000136830.65073.C7","journal-title":"Circulation"},{"key":"2951_CR7","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1182\/blood.V78.9.2337.2337","volume":"78","author":"HK Nieuwenhuis","year":"1991","unstructured":"Nieuwenhuis HK, Albada J, Banga JD, Sixma JJ (1991) Identification of risk factors for bleeding during treatment of acute venous thromboembolism with heparin or low molecular weight heparin. Blood 78:2337\u20132343. https:\/\/doi.org\/10.1182\/blood.V78.9.2337.2337","journal-title":"Blood"},{"key":"2951_CR8","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1592\/phco.29.6.631","volume":"29","author":"SA Spinler","year":"2009","unstructured":"Spinler SA, Ou FS, Roe MT, Gibler WB, Ohman EM, Pollack CV, Alexander KP, Peterson ED (2009) Weight-based dosing of enoxaparin in obese patients with non\u2010ST\u2010segment elevation acute coronary syndromes: results from the CRUSADE initiative. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 29:631\u2013638. https:\/\/doi.org\/10.1592\/phco.29.6.631","journal-title":"Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"},{"key":"2951_CR9","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1111\/j.1538-7836.2005.01304.x","volume":"3","author":"R Barba","year":"2005","unstructured":"Barba R, Marco J, Martin-Alvarez H, Rondon P, Fernandez\u2010Capitan C, Garcia\u2010Bragado F, Monreal M, RIETE investigators (2005) The influence of extreme body weight on clinical outcome of patients with venous thromboembolism: findings from a prospective registry (RIETE). J Thromb Haemost 3:856\u2013862. https:\/\/doi.org\/10.1111\/j.1538-7836.2005.01304.x","journal-title":"J Thromb Haemost"},{"key":"2951_CR10","unstructured":"Lexicomp, Online, July (2021) 30, https:\/\/online.lexi.com"},{"key":"2951_CR11","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.chest.2015.11.026","volume":"149","author":"C Kearon","year":"2016","unstructured":"Kearon C, Akl EA, Ornelas J, Blaivas A, Jimenez D, Bounameaux H, Huisman M, King CS, Morris TA, Sood N, Stevens SM (2016) Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest 149:315\u2013352. https:\/\/doi.org\/10.1016\/j.chest.2015.11.026","journal-title":"Chest"},{"key":"2951_CR12","doi-asserted-by":"publisher","first-page":"e545","DOI":"10.1016\/j.chest.2021.07.055","volume":"160","author":"SM Stevens","year":"2021","unstructured":"Stevens SM, Woller SC, Kreuziger LB, Bounameaux H, Doerschug K, Geersing GJ, Huisman MV, Kearon C, King CS, Knighton AJ, Lake E (2021) Antithrombotic therapy for VTE disease: second update of the CHEST guideline and expert panel report. Chest 160:e545\u2013608. https:\/\/doi.org\/10.1016\/j.chest.2021.07.055","journal-title":"Chest"},{"key":"2951_CR13","doi-asserted-by":"publisher","unstructured":"Witt DM, Nieuwlaat R, Clark NP, Ansell J, Holbrook A, Skov J, Shehab N, Mock J, Myers T, Dentali F, Crowther MA (2018) American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy. Blood advances. 2018;2:3257-91. https:\/\/doi.org\/10.1182\/bloodadvances.2018022954","DOI":"10.1182\/bloodadvances.2018022954"},{"key":"2951_CR14","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1177\/08971900211022300","volume":"36","author":"O Berger","year":"2021","unstructured":"Berger O, Sebaaly J, Crawford R, Rector K, Anderson W (2021) Evaluation of a treatment-dose enoxaparin protocol for patients with obesity. J Pharm Pract 36:74\u201378. https:\/\/doi.org\/10.1177\/08971900211022300","journal-title":"J Pharm Pract"},{"key":"2951_CR15","doi-asserted-by":"publisher","unstructured":"Lalama JT, Feeney ME, Vandiver JW, Beavers KD, Walter LN, McClintic JR (2015) Assessing an enoxaparin dosing protocol in morbidly obese patients. J Thromb Thrombolysis 39. https:\/\/doi.org\/10.1007\/s11239-014-1117-y. :516\u2009\u2013\u200921","DOI":"10.1007\/s11239-014-1117-y"},{"key":"2951_CR16","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s40261-019-00855-9","volume":"40","author":"YR Lee","year":"2020","unstructured":"Lee YR, Palmere PJ, Burton CE, Benavides TM (2020) Stratifying therapeutic enoxaparin dose in morbidly obese patients by BMI class: a retrospective cohort study. Clin Drug Investig 40:33\u201340. https:\/\/doi.org\/10.1007\/s40261-019-00855-9","journal-title":"Clin Drug Investig"},{"key":"2951_CR17","doi-asserted-by":"publisher","first-page":"094","DOI":"10.1055\/s-0038-1677019","volume":"45","author":"KH Maclachlan","year":"2019","unstructured":"Maclachlan KH, Stevens HP, Tran HA, Chunilal SD (2019) Weight-based enoxaparin for venous thromboembolism in obesity gives similar anti-xa levels to patients\u2009<\u2009100 kg, with no increase in major bleeding. InSeminars in Thrombosis and Hemostasis 45:094\u2013099. https:\/\/doi.org\/10.1055\/s-0038-1677019","journal-title":"InSeminars in Thrombosis and Hemostasis"},{"key":"2951_CR18","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1177\/1076029614568713","volume":"21","author":"NR Thompson-Moore","year":"2015","unstructured":"Thompson-Moore NR, Wanat MA, Putney DR, Liebl PH, Chandler WL, Muntz JE (2015) Evaluation and pharmacokinetics of treatment dose enoxaparin in hospitalized patients with morbid obesity. Clin Appl Thromb Hemost 21:513\u2013520. https:\/\/doi.org\/10.1177\/1076029614568713","journal-title":"Clin Appl Thromb Hemost"},{"key":"2951_CR19","doi-asserted-by":"publisher","unstructured":"van Oosterom N, Winckel K, Barras M (2019) Evaluation of weight based enoxaparin dosing on anti-xa concentrations in patients with obesity. J Thromb Thrombolysis 48. https:\/\/doi.org\/10.1007\/s11239-019-01847-4. :387\u2009\u2013\u200993","DOI":"10.1007\/s11239-019-01847-4"},{"key":"2951_CR20","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1002\/phar.1658","volume":"35","author":"YR Lee","year":"2015","unstructured":"Lee YR, Vega JA, Duong HN, Ballew A (2015) Monitoring enoxaparin with antifactor xa levels in obese patients. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 35:1007\u20131015. https:\/\/doi.org\/10.1002\/phar.1658","journal-title":"Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"},{"key":"2951_CR21","doi-asserted-by":"publisher","unstructured":"Curry MA, LaFollette JA, Alexander BR, Evans KS, Tran RH, Kempton CL (2019) Evaluation of treatment-dose enoxaparin in acutely ill morbidly obese patients at an academic medical center: a randomized clinical trial. Ann Pharmacother 53. https:\/\/doi-org.gate.lib.buffalo.edu\/https:\/\/doi.org\/10.1177\/1060028018821149. :567\u2009\u2013\u200973","DOI":"10.1177\/1060028018821149"},{"key":"2951_CR22","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.thromres.2004.10.004","volume":"116","author":"A Bazinet","year":"2005","unstructured":"Bazinet A, Almanric K, Brunet C, Turcotte I, Martineau J, Caron S, Blais N, Lalonde L (2005) Dose of enoxaparin among obese and renal impairment patients. Thromb Res 116:41\u201350. https:\/\/doi.org\/10.1016\/j.thromres.2004.10.004","journal-title":"Thromb Res"},{"key":"2951_CR23","doi-asserted-by":"publisher","unstructured":"Sacha GL, Greenlee KM, Ketz JM (2016) The use of anti-factor xa monitoring in a selection of patients receiving enoxaparin at a large academic medical center. J Thromb Thrombolysis 42. https:\/\/doi.org\/10.1007\/s11239-016-1384-x. :479\u2009\u2013\u200985","DOI":"10.1007\/s11239-016-1384-x"},{"key":"2951_CR24","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1111\/jth.13148","volume":"14","author":"N Khorsand","year":"2016","unstructured":"Khorsand N, Majeed A, Sarode R, Beyer-Westendorf J, Schulman S, Meijer K, Subcommittee on Control of Anticoagulation (2016) Assessment of effectiveness of major bleeding management: proposed definitions for effective hemostasis: communication from the SSC of the ISTH. J Thromb Haemost 14:211\u2013214. https:\/\/doi.org\/10.1111\/jth.13148","journal-title":"J Thromb Haemost"},{"key":"2951_CR25","unstructured":"Wells GA, Shea B, O\u2019Cnnell D et al (2023) The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. The Ottawa Hospital Research Institute website. Accessed November 16, https:\/\/www.ohri.ca\/\/programs\/clinical_epidemiology\/oxford.asp"},{"key":"2951_CR26","unstructured":"Cochrane Methods Bias. RoB 2: a revised Cochrane risk-of-bias tool for randomized trials. Cochrane Methods website. Accessed November 16 (2023) https:\/\/methods.cochrane.org\/bias\/resources\/rob-2-revised-cochrane-risk-bias-tool-randomized-trials"},{"key":"2951_CR27","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1007\/s11239-011-0584-7","volume":"32","author":"EN Deal","year":"2011","unstructured":"Deal EN, Hollands JM, Riney JN, Skrupky LP, Smith JR, Reichley RM (2011) Evaluation of therapeutic anticoagulation with enoxaparin and associated anti-xa monitoring in patients with morbid obesity: a case series. J Thromb Thrombolysis 32:188\u2013194. https:\/\/doi.org\/10.1007\/s11239-011-0584-7","journal-title":"J Thromb Thrombolysis"},{"key":"2951_CR28","doi-asserted-by":"publisher","first-page":"031","DOI":"10.1055\/s-2000-9497","volume":"26","author":"MM Samama","year":"2000","unstructured":"Samama MM, Gerotziafas GT (2000) Comparative pharmacokinetics of LMWHs. InSeminars in Thrombosis and Hemostasis 26:031\u2013038. https:\/\/doi.org\/10.1055\/s-2000-9497","journal-title":"InSeminars in Thrombosis and Hemostasis"},{"key":"2951_CR29","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1093\/ajhp\/60.7.683","volume":"60","author":"J Smith","year":"2003","unstructured":"Smith J, Canton M (2003) Weight-based administration of dalteparin in obese patients. Am J Health-Syst Pharm 60:683\u2013687","journal-title":"Am J Health-Syst Pharm"},{"key":"2951_CR30","first-page":"42","volume":"31","author":"JS Wilson","year":"2001","unstructured":"Wilson JS, Wilbur K, Burton E, Anderson D (2001) Effect of patient weight on the anticoagulant response to adjusted therapeutic dosage of low-molecular weight heparin for the treatment of venous thromboembolism. Haemostasis 31:42\u201348","journal-title":"Haemostasis"},{"key":"2951_CR31","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1055\/s-0037-1613090","volume":"87","author":"JW Hainer","year":"2002","unstructured":"Hainer JW, Barrett JS, Assaid CA, Fossler MJ, Cox DS, Leathers T, Leese PT (2002) Dosing in heavy-weight\/obese patients with the LMWH, tinzaparin: a pharmacodynamic study. Thromb Haemost 87:817\u2013823","journal-title":"Thromb Haemost"},{"key":"2951_CR32","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1001\/2013.jamainternmed.369","volume":"172","author":"DD DeCarolis","year":"2012","unstructured":"DeCarolis DD, Thorson JG, Clairmont MA, Leuthner AM, Rector TS, Johnson GJ (2012) Enoxaparin outcomes in patients with moderate renal impairment. Arch Intern Med 172:1713\u20131718. https:\/\/doi.org\/10.1001\/2013.jamainternmed.369","journal-title":"Arch Intern Med"},{"key":"2951_CR33","doi-asserted-by":"publisher","first-page":"2605","DOI":"10.1001\/archinte.162.22.2605","volume":"162","author":"J Nagge","year":"2002","unstructured":"Nagge J, Crowther M, Hirsh J (2002) Is impaired renal function a contraindication to the use of low-molecular-weight heparin? Arch Intern Med 162:2605\u20132609. https:\/\/doi.org\/10.1001\/archinte.162.22.2605","journal-title":"Arch Intern Med"},{"key":"2951_CR34","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1177\/1060028016631760","volume":"50","author":"NB Ha","year":"2016","unstructured":"Ha NB, Regal RE (2016) Anticoagulation in patients with cirrhosis: caught between a rock-liver and a hard place. Ann Pharmacother 50:402\u2013409. https:\/\/doi.org\/10.1177\/1060028016631760","journal-title":"Ann Pharmacother"},{"key":"2951_CR35","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1111\/j.1478-3231.2010.02358.x","volume":"31","author":"LP Bechmann","year":"2011","unstructured":"Bechmann LP, Sichau M, Wichert M, Gerken G, Kr\u00f6ger K, Hilgard P (2011) Low-molecular\u2010weight heparin in patients with advanced cirrhosis. Liver Int 31:75\u201382. https:\/\/doi.org\/10.1111\/j.1478-3231.2010.02358.x","journal-title":"Liver Int"},{"key":"2951_CR36","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/jp.2009.164","volume":"30","author":"E Friedrich","year":"2010","unstructured":"Friedrich E, Hameed AB (2010) Fluctuations in anti-factor xa levels with therapeutic enoxaparin anticoagulation in pregnancy. J Perinatol 30:253\u2013257. https:\/\/doi.org\/10.1038\/jp.2009.164","journal-title":"J Perinatol"},{"key":"2951_CR37","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1111\/jth.15358","volume":"19","author":"KA Martin","year":"2021","unstructured":"Martin KA, Beyer-Westendorf J, Davidson BL, Huisman MV, Sandset PM, Moll S (2021) Use of direct oral anticoagulants in patients with obesity for treatment and prevention of venous thromboembolism: updated communication from the ISTH SSC Subcommittee on Control of Anticoagulation. J Thromb Haemost 19:1874\u20131882. https:\/\/doi.org\/10.1111\/jth.15358","journal-title":"J Thromb Haemost"},{"key":"2951_CR38","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.thromres.2020.09.008","volume":"196","author":"T Delate","year":"2020","unstructured":"Delate T, Charlu M, Zhu S, Pai A, Clark NP, Witt DM, King JM, King JB (2020) Temporal trends in first-line outpatient anticoagulation treatment for cancer-associated venous thromboembolism. Thromb Res 196:367\u2013370. https:\/\/doi.org\/10.1016\/j.thromres.2020.09.008","journal-title":"Thromb Res"},{"key":"2951_CR39","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1200\/JCO.19.01461","volume":"41","author":"NS Key","year":"2023","unstructured":"Key NS, Khorana AA, Kuderer NM, Bohlke K, Lee AY, Arcelus JI, Wong SL, Balaban EP, Flowers CR, Gates LE, Kakkar AK (2023) Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO guideline update. J Clin Oncol 41:3063\u20133071. https:\/\/doi.org\/10.1200\/JCO.19.01461","journal-title":"J Clin Oncol"}],"container-title":["Journal of Thrombosis and Thrombolysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-024-02951-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11239-024-02951-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-024-02951-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T12:08:26Z","timestamp":1713442106000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11239-024-02951-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,25]]},"references-count":39,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,4]]}},"alternative-id":["2951"],"URL":"https:\/\/doi.org\/10.1007\/s11239-024-02951-w","relation":{},"ISSN":["1573-742X"],"issn-type":[{"value":"1573-742X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,25]]},"assertion":[{"value":"13 January 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no financial or non-financial interests that are directly or indirectly related to the work submitted for publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}